FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay
PMA: P210001
·
Supplement: S004
·
Decision Jul 21, 2022
Classifications
1
FEI Numbers
1
Registration Numbers
1
Basic Information
- Device Name
- Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay
- Trade Name
- VENTANA MMR RxDx Panel Solid Tumors with dMMR status)
- PMA Number
- P210001
- Supplement Number
- S004
- Device Class
- FDA Class 3
- Product Code
- QNH
- Generic Name
- Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay
- Regulation Number
- 864.1860
- Medical Specialty
- Hematology
- Advisory Committee
- Pathology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- July 21, 2022
- Date Received
- February 16, 2022
- Supplement Type
- Special (Immediate Track)
- Supplement Reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Expedited Review
- N
Advisory Committee Statement
Approval for (i) a change in expiry dating from Hematoxylin and Hematoxylin II and (ii) implementation of a revised process for creating reference slides used in Surveillance and Stability testing of Hematoxylin and Hematoxylin II.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| QNH | Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay | FDA class 3 | Hematology |